Literature DB >> 17595491

Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.

Rajvardhan Azad, Parijat Chandra.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17595491     DOI: 10.4103/0301-4738.33057

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
  5 in total

1.  Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity.

Authors:  Sjakon G Tahija; Rini Hersetyati; Geoffrey C Lam; Shunji Kusaka; Paul G McMenamin
Journal:  Br J Ophthalmol       Date:  2014-01-08       Impact factor: 4.638

2.  Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.

Authors:  Marcel N Menke; Carsten Framme; Mathias Nelle; Markus R Berger; Veit Sturm; Sebastian Wolf
Journal:  BMC Ophthalmol       Date:  2015-03-08       Impact factor: 2.209

3.  Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.

Authors:  Frank S Ong; Jane Z Kuo; Wei-Chi Wu; Ching-Yu Cheng; Wendell-Lamar B Blackwell; Brian L Taylor; Wayne W Grody; Jerome I Rotter; Chi-Chun Lai; Tien Y Wong
Journal:  J Pers Med       Date:  2013

Review 4.  Changing paradigms of anti-VEGF in the Indian scenario.

Authors:  P Mahesh Shanmugam
Journal:  Indian J Ophthalmol       Date:  2014-01       Impact factor: 1.848

5.  Survey of intravitreal injection techniques among retina specialists in Israel.

Authors:  Ori Segal; Yael Segal-Trivitz; Arie Y Nemet; Noa Geffen; Ronit Nesher; Michael Mimouni
Journal:  Clin Ophthalmol       Date:  2016-06-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.